Top Global Pharmaceutical Companies Weekly News Digest — October 21–27, 2024

【Answer 1】 • GSK (GlaxoSmithKline): On October 24, 2024, GlaxoSmithKline announced new preliminary data for AREXVY (an adjuvanted respiratory syncytial virus [RSV] vaccine) in adults aged 18–49 years whose risk of RSV-associated lower respiratory tract disease (LRTD) is increased due to certain underlying medical conditions, as well as in immunocompromised adults. These data suggest the vaccine may help protect a broader population of adults against potentially severe consequences of RSV infection. Currently, the vaccine is approved for active immunization to prevent RSV-LRTD in adults aged 60 years and older in over 50 countries, and in higher-risk adults aged 50–59 years in certain countries including the United States and Europe. Although disease burden exists in this younger at-risk population, no RSV vaccine is currently recommended for adults under age 60 who are at increased risk of RSV disease. In the Phase IIIb trial (NCT063894872), a single dose of the vaccine elicited robust immune responses in adults aged 18–49 years at increased risk of RSV-LRTD due to certain underlying medical conditions (n=395). Immune responses were non-inferior to those observed in adults aged 60 years and older (n=417), meeting the trial’s co-primary endpoints. In the Phase IIb trial (NCT059219033), a single dose of the vaccine induced strong immune responses in immunocompromised adults aged 18 years and older who had undergone kidney or lung transplantation (n=131); responses after a second dose (n=130) were comparable to those observed after a single dose (n=125) in healthy adults aged 50 years and older. These immune responses were consistent across all groups (receiving one or two doses targeting both RSV-A and RSV-B subtypes). These data will be presented at the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) meeting. In both studies, safety and reactogenicity profiles were consistent with results from the pivotal Phase III program that supported the vaccine’s initial approval. The most common local adverse event was pain; the most common systemic adverse events were fatigue, myalgia, arthralgia, and headache—most of which were transient and mild in intensity. Final results from these trials will be presented at upcoming medical conferences and submitted for peer-reviewed publication. The final data will also be submitted to the U.S. Food and Drug Administration (FDA) and other regulatory authorities to support potential label expansion. NCT06389487 is a Phase IIIb, open-label study designed to assess non-inferiority of immune response—and evaluate safety—of GSK’s RSV vaccine in adults aged 18–49 years at increased risk of RSV disease (n=395), compared with adults aged 60 years and older (n=417). A total of 1,457 participants were enrolled across 52 sites in six countries. The co-primary endpoints were neutralizing titers against RSV-A and RSV-B, expressed as geometric mean titer ratios (relative to older adults at increased risk), and seroresponse rates for RSV-A and RSV-B neutralizing titers one month post-vaccination. Safety and immunogenicity were also secondary endpoints.

Multinational Healthcare Companies | GSK (GlaxoSmithKline) Recruitment – A Global Leader in Pharmaceuticals

【Answer 2】 GlaxoSmithKline (GSK) is a global pharmaceutical company established in December 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, with its headquarters in London, UK. Focused on developing innovative medicines and vaccines, GSK reported revenue of £29.324 billion in 2022, with products distributed across global markets. Both predecessor companies trace their origins back to the mid-19th century, having each built world-leading positions in the pharmaceutical industry over more than a century through continuous innovation and multiple mergers. GSK focuses on immunological science, human genetics, and cutting-edge technologies, investing in four core therapeutic areas and future opportunities with large-scale health impact. 01 Benefits & Perks Reference ⭐️ Flexible, Life-Friendly Work: — Balanced mix of on-site and remote work, averaging 2–3 office days per week (varies by country/region); — 18 weeks of parental leave for primary and secondary caregivers; — Up to 4 weeks of paid leave to care for family members, during end-of-life situations, or in response to serious, acute health emergencies; — Financial wellness services and mental health training accessible to all employees; ⭐️ Compensation & Benefits: — Competitive base salary; — Annual bonus tied to company performance; — Employee recognition programs for outstanding achievements; — Access to healthcare and benefits plans, pension schemes, savings plans, paid time off, and childcare support incentives; ⭐️ Health Protection: — GSK offers 40+ preventive health screenings and protections; — Employee-exclusive flexible benefits (covering health, risk management, etc.); — Access to comprehensive healthcare and benefits programs; 02 Pathways into Multinational Companies 1. Company Career Websites Directly checking job openings on multinational companies’ official websites and applying there is effective—but time-consuming. Also, the specific role you seek may not currently be open. 2. Official Accounts of Business Chambers e.g., 【European Chamber】, 【AmCham China】, 【German Chamber SH】 These are highly useful: they connect you with networks of multinational enterprises (MNEs) in China and abroad, regularly post job listings, and share industry insights. Few job seekers currently use this channel—so it’s an excellent opportunity to find hidden gems. They feature dedicated ‘Jobs’ sections listing current vacancies, along with updates on MNE industry trends and developments. 3. Jingke (Jingke Platform) We recommend Jingke because many multinational companies—including GSK—post newly opened positions there. You can search directly on the platform! It also displays, in real time, how many open positions a given MNE currently has. Clicking into any individual company reveals detailed corporate information, benefits, and more.

GSK to Invest Over $800 Million in Pennsylvania Biopharma Hub, Creating 300 Jobs

Oct 9, 2026

GSK plans to invest over $800 million to expand its Pennsylvania site into a biopharmaceutical hub, creating 300 new jobs by 2027. The facility will support clinical and commercial production of biologics.

reuters

2026-07-28

GSK to Cut Jobs Amid £1.9bn Cost-Cutting Plan and Bid for Faster Drug Development

2026-10-09

GSK to Invest Over $800 Million in Pennsylvania Biopharma Hub, Creating 300 Jobs

GSK to Invest Over $800 Million in Pennsylvania Biopharma Hub, Creating 300 Jobs

FAQ